Mate Act Explained
Join us for a brief informational presentation on the Mate Act – hope this helps answer all your questions!
Mate Act Explained Read More »
The UK Personal Independence Payment Database – Should Spiraling Disabilities Give Pause To Reconsider Continued Routine Office Based Anesthesia In Dentistry Without Further Consideration?
Former Blackrock hedge fund analyst Ed Dowd made a troubling discovery about mortality rates in the US. He observed an increase in deaths, particularly among young individuals, unrelated to COVID-19. Insurance companies also reported higher death rates. Dowd’s research team has now found startling data from the UK indicating a significant rise in disabilities coinciding with the mass vaccination effort. Dowd believes the same trend is likely happening in the US. This raises concerns, especially in dentistry, where an increase in cardiovascular disabilities among young patients has been observed. A more cautious approach to office-based anesthesia may be necessary.
Fluoride: A Second Look…
Many of us learned about the advantages of fluoride in dental school. However, in the post-COVID pandemic era, people are reevaluating widely accepted beliefs, including fluoride. Anti-fluoridation proponents have presented valid arguments.  Join the Socratic Dental Alliance and watch a video of a recent meeting with two notable advocates, Rick North and Barbara Tritz, to
Fluoride: A Second Look… Read More »
DEA Issues Guidance on Opioid Treatment Training for Medical Practitioners
The US Drug Enforcement Administration (DEA) has outlined an eight-hour training requirement on the treatment and management of opioid patients. The Medication Access and Training Expansion Act mandates the training for all DEA-registered providers, with the deadline for completion set for the date of a practitioner’s next scheduled DEA registration submission beginning on June 27. Graduates from medical and dental schools are exempt from the requirement. The training does not have to occur in one session, and courses previously undertaken in accordance with state-mandated continuing education will apply.
DEA Issues Guidance on Opioid Treatment Training for Medical Practitioners Read More »
FDA Approves OTC Naloxone
This article discusses the recent approval of the first over-the-counter naloxone nasal spray for use in reversing opioid overdoses. The U.S. Food and Drug Administration (FDA) has approved the first over-the-counter (OTC) naloxone nasal spray, Narcan, to help prevent opioid overdoses. The nasal spray is intended for use in adults and adolescents, and the FDA
FDA Approves OTC Naloxone Read More »
Update: MATE Act
The ADA has issued a FAQ (frequently asked questions) providing additional information regarding the 2022 Omnibus Bill with provisions for the MATE Act – which included a controlled substance education requirement for continuing DEA registration. The FAQ suggests further information and guidance will be forthcoming by the end of March. The Act contains exclusions and
MATE Act
It has come to our attention a little known provision of the federal omnibus bill approved in the waning hours of 2022 included a requirement that could impact your practice if not properly managed. The Medication Access and Training Expansion (MATE) Act, which aims to improve access to medications and expand training for healthcare professionals
Antihistamines A common Contributor In Opioid Overdose Deaths?
A recent CDC analysis shows that antihistamines, particularly first-generation H1 subtype antihistamines like diphenhydramine, play a role in drug overdoses. Opioids were involved in most cases, and naloxone may not work with antihistamines. Continual monitoring is important.
Antihistamines A common Contributor In Opioid Overdose Deaths? Read More »
Must Read…
Discover the greatest sage wisdom through a must-read book. Purchase it and start putting it into practice today.
FDA alerts health care professionals of risks to patients exposed to xylazine in illicit drugs
Healthcare professionals have been alerted by the FDA to the dangers of patients being exposed to xylazine, a veterinary sedative, in illicit drugs. The FDA advises healthcare professionals to report any adverse events related to xylazine.